In glioblastoma, the oncometabolite D-2-hydroxyglutarate (D-2-HG), produced by IDH-mutant tumor cells, is taken up by CD8+ T cells, altering their metabolism and impairing cytotoxicity (Notarangelo et al., 2022). Here, CD8A is linked to neoplasm.